The Asia Pacific Pain Patch Market would witness market growth of 5.2% CAGR during the forecast period (2023-2029).
The pain patch provides the benefit of controlled medication distribution over alternative administration techniques because it uses a transdermal route. Generic and brand-name Duragesic medications with transdermal fentanyl patches are both available. Fentanyl is a common medication for treating acute pain since it is an opioid with a rapid onset of pain relief. Fentanyl patches can provide pain relief for up to 72 hours after being applied to the skin.
Patients with a range of primary neurological illnesses are adversely affected by persistent pain, which is a frequent hallmark of many neurodegenerative syndromes. The market for pain relief is being driven by the fact that a number of pathophysiological problems, such as severe trauma to the central nervous system, neuroinflammation, and nerve pain, bring on these disorders. Dementia, Alzheimer's, Parkinson's disease, and other neurological disorders are more prevalent in the elderly. The market for pain patches is anticipated to increase significantly over the next several years due to a sharp growth in the geriatric population.
In India, more than a million new cancer cases are identified each year, and it is predicted that this number will nearly triple over the next 20 years. In late cancer stages, pain occurrence rates are between 70% and 80%. The prevalence of pain was found to be 39.3% after curative treatment, 55.0% (95% CI 45.9-64.2) during anticancer treatment, 66.4% (95% CI 58.1-74.7) in advanced, metastatic, or terminal disease, and 50.7% (95% CI 37.2-64.1) in all cancer stages, with accordance to various studies on cancer pain. It was further seen that 38.0% of cancer patients had moderate-to-severe pain. Therefore, provide growth opportunities for the pain patch market in the region.
The China market dominated the Asia Pacific Pain Patch Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $535.4 million by 2029. The Japan market is estimated to grow a CAGR of 4.5% during (2023 - 2029). Additionally, The India market would experience a CAGR of 5.8% during (2023 - 2029).
Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Type, the market is segmented into Prescription Medicines and OTC Medicines. Based on Product Type, the market is segmented into Non-Opioid Patches and Opioid Patches. Based on Non-Opioid Patches Type, the market is segmented into Nonsteroidal Anti-Inflammatory Drugs, Methyl Salicylate, Lidocaine and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Pain Patch Market is Projected to reach USD 6.4 Billion by 2029, at a CAGR of 4.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include NEXGEL, Inc. Viatris, Inc. Johnson & Johnson. Teva Pharmaceutical Industries Ltd. Grunenthal GmbH. Sorrento Therapeutics, Inc. Hisamitsu Pharmaceutical Co. Inc. Endo International PLC. Purdue Pharma L.P. Amneal Pharmaceuticals, Inc.
By Distribution Channel
By Type
By Product Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
